Biology-driven cancer drug development: back to the future

Por Lord, Christopher J, Ashworth, Alan
Publicado em 2010

PARP Inhibitors: The First Synthetic Lethal Targeted Therapy

Por Lord, Christopher J., Ashworth, Alan
Publicado no Science (2017)

Nuclear envelope–vacuole contacts mitigate nuclear pore complex assembly stress

Por Lord, Christopher L., Wente, Susan R.
Publicado no J Cell Biol (2020)

The Highly Conserved COPII Coat Complex Sorts Cargo from the Endoplasmic Reticulum and Targets It to the Golgi

Por Lord, Christopher, Ferro-Novick, Susan, Miller, Elizabeth A.
Publicado em 2013

Nup100 regulates Saccharomyces cerevisiae replicative life span by mediating the nuclear export of specific tRNAs

Por Lord, Christopher L., Ospovat, Ophir, Wente, Susan R.
Publicado no RNA (2017)

Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions

Por Lord, Christopher J, Quinn, Niall, Ryan, Colm J
Publicado no eLife (2020)

NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells

Por Mendes-Pereira, Ana M., Lord, Christopher J., Ashworth, Alan
Publicado em 2012

Driver oncogenes but not as we know them - targetable fusion genes in breast cancer

Por Natrajan, Rachael, Tutt, Andrew N. J., Lord, Christopher J.
Publicado no Cancer Discov (2018)

CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer

Por Bridgett, Stephen, Campbell, James, Lord, Christopher J., Ryan, Colm J.
Publicado no Cell Syst (2017)

An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence

Por Rovillain, Emilie, Mansfield, Louise, Lord, Christopher J, Ashworth, Alan, Jat, Parmjit S
Publicado em 2011

Directing the use of DDR kinase inhibitors in cancer treatment

Por Brandsma, Inger, Fleuren, Emmy D.G., Williamson, Chris T., Lord, Christopher J.
Publicado no Expert Opin Investig Drugs (2017)

A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine

Por Nyamundanda, Gift, Eason, Katherine, Guinney, Justin, Lord, Christopher J., Sadanandam, Anguraj
Publicado no Cancers (Basel) (2020)

Altering nuclear pore complex function impacts longevity and mitochondrial function in S. cerevisiae

Por Lord, Christopher L., Timney, Benjamin L., Rout, Michael P., Wente, Susan R.
Publicado no J Cell Biol (2015)

A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events

Por Ryan, Colm J., Kennedy, Susan, Bajrami, Ilirjana, Matallanas, David, Lord, Christopher J.
Publicado no Cell Syst (2017)

Beyond DNA repair: the novel immunological potential of PARP inhibitors

Por Chabanon, Roman M., Soria, Jean-Charles, Lord, Christopher J., Postel-Vinay, Sophie
Publicado no Mol Cell Oncol (2019)

DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells

Por Gudmundsdottir, Katrin, Lord, Christopher J, Witt, Emily, Tutt, Andrew N J, Ashworth, Alan
Publicado em 2004

Structural basis for recruitment of BRCA2 by PALB2

Por Oliver, Antony W, Swift, Sally, Lord, Christopher J, Ashworth, Alan, Pearl, Laurence H
Publicado em 2009

Structural basis for recruitment of BRCA2 by PALB2

Por Oliver, Antony W, Swift, Sally, Lord, Christopher J, Ashworth, Alan, Pearl, Laurence H
Publicado no EMBO Rep (2017)

Ultrasound-guided muscle biopsy: a practical alternative for investigation of myopathy

Por Raithatha, Anish, Ashraghi, Mohammad Reza, Lord, Christopher, Limback-Stanic, Clara, Viegas, Stuart, Amiras, Dimitri
Publicado no Skeletal Radiol (2020)

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity

Por Frankum, Jessica, Moudry, Pavel, Brough, Rachel, Hodny, Zdenek, Ashworth, Alan, Bartek, Jiri, Lord, Christopher J.
Publicado no Oncotarget (2015)